stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −410.0%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) Return on equity
PTC Therapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was 61.1%, up 165.8 percentage points from fiscal 2025 (−104.8%). Over the past ten years it has ranged from −216.8% (fiscal 2021) to 323.5% (fiscal 2022); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −104.8% | (142.66) |
| FY2024 | 37.9% | (69.60) |
| FY2023 | 107.5% | (215.95) |
| FY2022 | 323.5% | 540.21 |
| FY2021 | −216.8% | (135.33) |
| FY2020 | −81.4% | (28.18) |
| FY2019 | −53.2% | (2.73) |
| FY2018 | −50.5% | 6.73 |
| FY2017 | −57.2% | 25.00 |
| FY2016 | −82.2% | (17.24) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PTCT PTC Therapeutics, Inc. | 61.1% |
| MANE Veradermics Incorporated compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| CGON CG Oncology, Inc. compare | −26.4% |
| IMVT Immunovant, Inc. compare | −80.1% |
| COGT Cogent Biosciences, Inc. compare | −146.6% |
| SRRK Scholar Rock Holding Corporation compare | −167.8% |
| KOD Kodiak Sciences Inc. compare | −368.4% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −760.0% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on PTCT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement